With Brexit looming, many are interested in potential impacts on the medical research space. Our CEO, Pablo Graiver, spoke with Drug Development Technology, to share his thoughts on this issue.
"Britain’s impending departure from the EU has raised a host of concerns in the drug development industry. In particular, worries have been voiced over the UK’s possible exclusion from funding opportunities and regulatory bodies such as the European Medicines Agency (EMA)..."
Read more at DrugDevelopment-Technology.com.